The U. S. Food and Drug Administration had finally permitted the AstraZeneca PLC's anticlotting Brilinta medicine, which was also entitled with its generic name- Ticagrelor.

The drug was approved after an FDA advisory nonagency medical expert’s panel reviewed the drug and 9-to-6 members voted against a proposed diabetes drug- dapagliflozin. The experts claimed that the clinical test proved that as compared to Plavix, which is used to prevent heart attacks and deaths, the drug was more effective.

Meanwhile, the drug was labeled with the FDA's toughest boxed warning, which stated that aspirin doses above 100 milligrams would definitely reduce the products’ effectiveness and patients would also suffer from bleeding risks.

Dr. Alex Gold, the company’s brand development leader added, “It’s good news for patients, and it’s a good result for AstraZeneca as well and we think the label has been a good outcome and will enable physicians to use the drug appropriately”.

The drug would be used to separately keep the blood platelets, so that the blood clot procedure could be stopped, which would definitely reduce the chances of heart attack and strokes.

Soon the drug would be entering the market and all the sensitive coronary syndrome detected patients would be cured with the powerful drug.